Non Alcoholic Steatohepatitis Treatment Market
According to Intent Market Research, the Non-Alcoholic Steatohepatitis Treatment Market is expected to grow from USD 9.1 Billion in 2024-e at a CAGR of 23.4% to touch USD 31.9 Billion by 2030. The Non-Alcoholic Steatohepatitis Treatment Market is dominated by key players such as, Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Eli Lilly and Co., Novo Nordisk A/S, Bristol-Myers Squibb Company, and Pfizer, Inc..